Canadian Patent Issued for Rockwell Medical's (RMTI) Proprietary SFP-Iron Delivery
Rockwell Medical (NASDAQ: RMTI) announced today that it has received notice from the Canadian Intellectual Property Office that it has obtained patent issuance for its proprietary drug, Soluble Ferric Pyrophosphate (SFP), the Company's late-stage investigational drug that provides iron replacement to hemodialysis patients with CKD. The Canadian patent grant covers the method and pharmaceutical composition for SFP-iron delivery in hemodialysis and peritoneal dialysis patients.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA/Merrill Lynch Starts Rockwell Medical Technologies (RMTI) at Buy
- Rockwell Medical (RMTI) Price Target Raised at Oppenheimer Amid Triferic Approval, Label In-Line with Expectations
- AT&T (T) Biggest Bidder in Airwaves Auction; DISH Network (DISH) Stock Pressured
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!